Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729641 | 0.99 | KDM4E (0.60) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL28146940 | 0.84 | HTT (0.44) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL321639 | 0.80 | ALDH1A1 (0.83) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL31022581 | 0.80 | ALDH1A1 (0.83) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL2729633 | 0.80 | ALDH1A1 (0.83) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL28061597 | 0.78 | MCL1 (0.72) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL8402004 | 0.78 | MCL1 (0.72) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL8359452 | 0.78 | MCL1 (0.72) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL11442137 | 0.78 | MCL1 (0.72) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL12986976 | 0.77 | KDM4E (0.77) | KDM4EHTTNCOA3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170159105-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9574220-B2 | Enzyme assays on a droplet actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2516669-B1 | ENZYME ASSAYS ON A DROPLET ACTUATOR | ADVANCED LIQUID LOGIC INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150184219-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9012165-B2 | Assay for B-galactosidase activity | ADVANCED LIQUID LOGIC, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140141460-A1 | Method of Conducting an Assay | ADVANCED LIQUID LOGIC, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8592217-B2 | Method of conducting an assay | ADVANCED LIQUID LOGIC, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130130936-A1 | Method of Conducting an Assay | ADVANCED LIQUID LOGIC, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8394641-B2 | Method of hydrolyzing an enzymatic substrate | ADVANCED LIQUID LOGIC INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2516669-A2 | ENZYME ASSAYS ON A DROPLET ACTUATOR | Advanced Liquid Logic, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120136147-A1 | Method of hydrolyzing an enzymatic substrate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-31 | — | — | US | disclosed |
| US-8093062-B2 | Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-10 | — | — | US | disclosed |
| WO-2011084703-A2 | ENZYME ASSAYS ON A DROPLET ACTUATOR | ADVANCED LIQUID LOGIC, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110118132-A1 | Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil | ADVANCED LIQUID LOGIC, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150184219-A1 | Enzyme Assays on a Droplet Actuator | IDE, UCHL3, UGDH | KDM4E 2289/4885HTT 3013/4885NCOA3 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.